High Tower Advisors, LLC Bei Gene, Ltd. Transaction History

High Tower Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$221.31 - $316.61 $5.95 Million - $8.51 Million	-26,875 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$189.18 - $286.44 $280,364 - $424,504	-1,482 Reduced 5.23%	26,875 $7.7 Million
Q2 2020 Aug 10, 2020	BUY	$123.9 - $195.41 $41,506 - $65,462	335 Added 1.2%	28,357 $5.34 Million
Q1 2020 May 21, 2020	BUY	$121.84 - $173.19 $236,247 - $335,815	1,939 Added 7.43%	28,022 $3.42 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $476,782 - $857,944	-4,118 Reduced 13.64%	26,083 $4.27 Million
Q3 2019 Nov 12, 2019	BUY	$120.61 - $148.29 $3.64 Million - $4.48 Million	30,201 New	30,201 $3.68 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.